Estrogen replacement therapy and the risk of venous thrombosis☆
References (50)
Oestrogen replacement therapy: physiological considerations and new applications
Baillieres Clin Endocrinol Metab
(1987)- et al.
Estrogen therapy during menopause and the treatment of osteoporosis
Prim Care
(1990) Hormonal replacement therapy: benefits, risks, doses
Med Clin North Am
(1987)- et al.
Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies
Am J Obstet Gynecol
(1985) - et al.
Hormonal contraception and thromboembolic disease: effects of the oral contraceptives on hemostatic mechanisms
J Chron Dis
(1971) - et al.
Treatment of uraemic bleeding with conjugated oestrogen
Lancet
(1984) - et al.
Equine estrogen-dydrogesterone therapy in the management of postmenopausal women
Eur J Obstet Gynecol Reprod Biol
(1986) - et al.
Effect of hormone replacement therapy on anti-thrombin III activity in post menopausal women
Int J Gynaecol Obstet
(1986) Update: cardiovascular effects of oral contraception and hormonal replacement therapy
Am J Obstet Gynecol
(1988)The menopause
Invest Radiol
(1986)
The menopause: benefits and risks of estrogen-progestogen replacement therapy
Fertil Steril
Prevention of osteoporosis: treatment of estradiol deficiency
Obstet Gynecol
Hip fracture and the use of estrogens in postmenopausal women
N Engl J Med
Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormonereplacement therapy
N Engl J Med
Estrogen use and coronary heart disease in women
JAMA
Cardiovascular implications of estrogen replacement therapy
Obstet Gynecol
Postmenopausal estrogen therapy and cardiovascular disease
N Engl J Med
Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
N Engl J Med
Decreased mortality in users of estrogen replacement therapy
Arch Intern Med
Increased risk of endometrial carcinoma among users of conjugated estrogens
N Engl J Med
Estrogens and endometrial cancer in a retirement community
N Engl J Med
Endometrial cancer and estrogen use
N Engl J Med
Surgically confirmed gallbladder disease, venous thromboembolism and breast tumors in relation to postmenopausal estrogen therapy
N Engl J Med
Putative complications of estrogen replacement therapy: hypertension, diabetes, thrombophlebitis, and gallstones
Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
Obstet Gynecol
Cited by (172)
Hormone replacement therapy and venous thromboembolism
2014, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :Three of these were small case-control studies. These included the Boston Collaborative Drug Surveillance Program (RR 2.3 95% CI, 0.6–8.0), Petitti et al. (RR 0.7 95% CI 0.2–2.5), and Devor et al. (RR 0.6 95% CI 0.2–1.8) [4–6]. Devor et al. included the greatest number of incident VTE – 121 cases – in a study based at a single academic medical center [5].
Estrogen and progestogen therapy in postmenopausal women
2008, Fertility and SterilityCitation Excerpt :Data from epidemiologic studies and RCTs consistently demonstrate an increased risk of VTE events in postmenopausal women who use ET or E/PT (24, 26, 71, 72). In five epidemiologic studies published between 1992 and 1997 involving 592 cases of VTE of which 130 (22.0%) were current HT users, the risk of VTE was increased approximately two-fold (typical OR 2.3; 95% CI, 1.7–3.0) (73–77). In the HERS trial, the relative risk of VTE was similar in magnitude: 2.66 (95% CI, 1.41–5.04) (62).
Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study
2007, Fertility and SterilityCitation Excerpt :The risk is increased in persons who have undergone recent surgical procedures and in those with previous VTE, immobilization, fractures of the lower extremities, and inherited coagulation disorders (19). The incidence of VTE in women increases after menopause (20), and evidence concerning the effect of HT on the risk of VTE is contradictory (4–12). We examined the effect of tibolone and conjugated E on hemostasis in surgically menopausal patients in whom immediate replacement therapy was started postoperatively.
Risk of pulmonary embolism/venous thrombosis
2007, MenopauseRisk of Pulmonary Embolism/Venous Thrombosis
2007, Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Third EditionEstrogen and progestogen therapy in postmenopausal women
2006, Fertility and Sterility
- ☆
This research was supported in part by the National Institutes of Health and the National Heart, Lung and Blood Institute Grant 1U01-HL40207. This work was presented in abstract form at the Annual Meeting of the Society of General Internal Medicine, Arlington, Virginia, May 1990.